Ameriprise
OMED

Ameriprise’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Ameriprise’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-283,220
Closed -$654K – 3863
2018
Q2 		$654K Sell
283,220
-21,100
-7% -$61.4K ﹤0.01% 3165
2018
Q1 		$968K Sell
304,320
-656,817
-68% -$1.81M ﹤0.01% 2984
2017
Q4 		$3.94M Buy
961,137
+49,953
+5% +$217K ﹤0.01% 2291
2017
Q3 		$4.12M Sell
911,184
-55,811
-6% -$226K ﹤0.01% 2226
2017
Q2 		$3.22M Buy
966,995
+286,545
+42% +$1.19M ﹤0.01% 2365
2017
Q1 		$6.27M Buy
+680,450
New +$5.98M ﹤0.01% 1867
2014
Q4 		– Sell
-15
Closed – – 5395
2014
Q3 		$0 Sell
15
-15
-50% -$301 ﹤0.01% 6166
2014
Q2 		$1K Buy
+30
New +$741 ﹤0.01% 5508
2013
Q4 		– Sell
-13,500
Closed -$207K – 5917
2013
Q3 		$207K Buy
+13,500
New +$250K ﹤0.01% 3169

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2B AUM 117.41% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return